SCHEMBL9948136

SCHEMBL9948136

CO[C@]1(C)CC[C@]2(CC1)Cc1ccc(Br)cc1C2=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.43
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
BRD4 O60885 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
TDP2 O95551 1/20 0.34
PARP1 P09874 1/20 0.34
PARP10 Q53GL7 1/20 0.34
MALT1 Q9UDY8 1/20 0.33
TGM2 P21980 1/20 0.33
CES1 P23141 1/20 0.33
BACE1 P56817 5/20 0.33
CMA1 P23946 1/20 0.33
AHR P35869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9948135 1.00 APP (0.43) APPTDP1L3MBTL1MEN1KMT2A
SCHEMBL10249617 1.00 APP (0.43) APPTDP1L3MBTL1MEN1KMT2A
SCHEMBL9948162 0.87 TDP1 (0.46) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL10250331 0.83 APP (0.43) APPMEN1KMT2ABRD4PDE4B
SCHEMBL9948563 0.83 APP (0.43) APPMEN1KMT2ABRD4PDE4B
SCHEMBL9948564 0.83 APP (0.43) APPMEN1KMT2ABRD4PDE4B
SCHEMBL10249815 0.83 CA1 (0.42) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL9947977 0.83 CA1 (0.42) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL9948406 0.83 CA1 (0.42) TDP1L3MBTL1MEN1KMT2ABRD4
SCHEMBL19567346 0.81 APP (0.53) APPBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3176172-B1 SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2020-01-29 EP disclosed
US-10231967-B2 Compounds and their use as BACE inhibitors ASTRAZENECA AB (SE) 2019-03-19 US disclosed
US-20180221367-A1 COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2018-08-09 US disclosed
US-9918985-B2 Compounds and their use as BACE inhibitors ASTRAZENECA AB (SE) 2018-03-20 US disclosed
US-20170319578-A1 COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2017-11-09 US disclosed
EP-3176172-A1 SPIROIMIDAZOLE COMPOUNDS AND THEIR USE AS BACE INHIBITORS Astrazeneca AB (SE) 2017-06-07 EP disclosed
EP-2655378-B1 COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2017-03-01 EP disclosed
US-20160184303-A1 COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2016-06-30 US disclosed
US-9248129-B2 Compounds and their use as BACE inhibitors ASTRAZENECA AB (SE) 2016-02-02 US disclosed
US-20150133471-A1 COMPOUNDS AND THEIR USE AS BACE INHIBITORS ASTRAZENECA AB (SE) 2015-05-14 US disclosed
US-8865911-B2 Compounds and their use as BACE inhibitors ASTRAZENECA AB (SE) 2014-10-21 US disclosed
US-20130210837-A1 Compounds and Their Use as BACE Inhibitors ASTRAZENECA INTELLECTUAL PROPERTY 2013-08-15 US disclosed
US-8415483-B2 Compounds and their use as BACE inhibitors ASTRAZENECA AB (SE) 2013-04-09 US disclosed
US-20120165347-A1 Compounds and their use as BACE Inhibitors ASTRAZENECA AB (SE) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133471-A1 COMPOUNDS AND THEIR USE AS BACE INHIBITORS BACE1, BACE2, APP APP 3/4885TDP1 82/4885L3MBTL1 3800/4885
US-20120165347-A1 Compounds and their use as BACE Inhibitors BACE1, BACE2, APP APP 3/4885TDP1 82/4885L3MBTL1 3800/4885
US-20130210837-A1 Compounds and Their Use as BACE Inhibitors BACE1, BACE2, APP APP 3/4885TDP1 82/4885L3MBTL1 3800/4885
US-10231967-B2 Compounds and their use as BACE inhibitors BACE1, BACE2, APP APP 3/4885TDP1 82/4885L3MBTL1 3800/4885
US-20180221367-A1 COMPOUNDS AND THEIR USE AS BACE INHIBITORS BACE1, BACE2, APP APP 3/4885TDP1 82/4885L3MBTL1 3800/4885
US-20160184303-A1 COMPOUNDS AND THEIR USE AS BACE INHIBITORS BACE1, BACE2, APP APP 3/4885TDP1 82/4885L3MBTL1 3800/4885
US-20170319578-A1 COMPOUNDS AND THEIR USE AS BACE INHIBITORS BACE1, BACE2, APP APP 3/4885TDP1 82/4885L3MBTL1 3800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.